Thromboembolic risk in dermatomyositis patients treated with intravenous immunoglobulin: a retrospective cohort study

Published: 24 February 2025| Version 2 | DOI: 10.17632/d9w3g87h4v.2
Contributors:
Crystal Chang, Sara Khattab

Description

Supplementary data for "Thromboembolic risk in dermatomyositis patients treated with intravenous immunoglobulin: a retrospective cohort study." Method S1 IVIg definition Method S2 Exclusion criteria Method S3 Flow diagram of study design Method S4 Matching and propensity score plots Analysis SI Analysis requiring 2 DM diagnoses for study inclusion: baseline characteristics Analysis SII Analysis requiring 2 DM diagnoses for study inclusion: propensity score plots Analysis SIII Analysis requiring 2 DM diagnoses for study inclusion: IVIg vs. non-IVIg systemic and IVIg vs. no systemic treatment Analysis SIV Analysis of TE events up to 6 months following IVIg: baseline characteristics Analysis SV Analysis of TE events up to 6 months following IVIg: propensity score plots Analysis SVI Analysis of TE events up to 6 months following IVIg: IVIg vs. non-IVIg systemic and IVIg vs. no systemic treatment

Files

Categories

Dermatology, Dermatomyositis, Intravenous Immunoglobulin Therapy

Licence